Phosphodiesterase 7B1 as Therapeutic Target for Treatment of Cognitive Dysfunctions in Multiple Sclerosis
Arthi Balsundaram1★, Darling Chellathai1★ Corresponding author
- 1Department of Pharmacology, Sri Ramachandra Medical College and Research Institute, Chennai, Tamil Nadu, India.
CORRESPONDENCE
Arthi Balsundaram
Department of Pharmacology, Sri Ramachandra Medical College and Research Institute, Chennai, Tamil Nadu, India.
Received: 11-06-2018; Revised: 12-08-2018; Accepted: 12-10-2018.
Volume 9, Issue 3 · pp. 126–30 · PUBLISHED 2018 · DOI: 10.4103/jpp.JPP_77_18
View on J Pharmacol. Pharmacother. original site ↗
ABSTRACT
Multiple sclerosis (MS) is an autoimmune, chronic degenerative neuroinflammatory disorder affecting younger age groups of the United States of America and Europe. MS prevalence studies in India have shown that India is no longer a low‑risk zone. Many studies have shown the seriousness of cognitive impairments (CIs) and its types caused in MS. In this review, the pathological basis for CI in various stages of MS was reviewed and revealed to provide a basis for the treatment. Role of phosphodiesterase 7B1 (PDE7B1) inhibitors in treating CI related to MS were also stated in this review. The literature for this review was collected from PubMed and Embase.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Balsundaram, A., & Chellathai, D. (2018). Phosphodiesterase 7B1 as Therapeutic Target for Treatment of Cognitive Dysfunctions in Multiple Sclerosis. Journal of Pharmacology and Pharmacotherapeutics, 9(3), 126–30. https://doi.org/10.4103/jpp.JPP_77_18